This is a working overview of PNB-0408, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-25. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
=== Functional analogues and derivatives === 3,3-Difluoroalanine: Difluorinated alanine with similar residue hydrophobicity to that of isoleucine. 3,3,3-Trifluoroalanine: Trifluorinated alanine that expresses properties of a suicide inhibitor for alanine racemases. 3,3,3-Trifluoroalanine N-carboxyanhydride: A cyclic anhydride of trifluorinated alanine investigated for use as a monomer in homo- and co-polymerisations.
Risk of addiction and abuse Potentially fatal respiratory depression Lethal overdose in accidental ingestion QT prolongation Neonatal opioid withdrawal syndrome in children of pregnant women CYP450 drug interactions Risks when used with alcohol, benzodiazepines, and other CNS depressants. A certified opioid treatment program is required under federal law (42 CFR 8.12) when dispensing methadone for the treatment of opioid addiction.
== External links == H. E. Carter & Minor J. Coon: William Cumming Rose from National Academy of Sciences Daphne A. Roe (1981) William Cumming Rose: A biographical sketch Journal of Nutrition 111(8):1311–20. Noyes Laboratory at the University of Illinois, Urbana-Champaign from American Chemical Society National Historic Chemical Landmarks William C. Rose Papers, University of Illinois Archives https://loguepedia.com/william-rose-american-scientist/
Sources: en.wikipedia.org
Alternative pathway of endogenous antigen processing and presentation over MHC-II molecules exists in medullary thymic epithelial cells (mTEC) via the process of autophagy. It is important for the process of central tolerance of T cells in particular the negative selection of autoreactive clones. Random gene expression of the whole genome is achieved via the action of AIRE and a self-digestion of the expressed molecules presented on both MHC-I and MHC-II molecules.
Hydrostatic skeletons are flexible cavities within an animal that provide structure through fluid pressure, occurring in some types of soft-bodied organisms, including jellyfish, flatworms, nematodes, and earthworms. The walls of these cavities are made of muscle and connective tissue. In addition to providing structure for an animal's body, hydrostatic skeletons transmit the forces of muscle contraction, allowing an animal to move by alternating contractions and expansions of muscles along the animal's length.
== Origins == Due to the long, tedious process of analyzing proteins, peptide mass fingerprinting was developed. Edman degradation was used in protein analysis, and it required almost an hour to analyze one amino acid residue. SDS-PAGE was also used to separate proteins in very complex mixtures, which also employed methods of electroblotting and staining. Then, bands would be extracted from the gel and sequenced, automatically. A recurring problem in the process was that interfering proteins would also purify with the protein of interest. The sequences of these interfering proteins were compiled into what came to known as the Dayhoff database. Ultimately, having the sequences of these known protein contaminants in databases decreased instrument time and expenses involved in protein analysis.
Sources: en.wikipedia.org
Massively parallel reporter assays (MPRAs) and machine learning are newer ways to study gene regulation with reporter genes. One major use is in synthetic biology and gene therapy, where researchers can design better regulatory elements to control gene expression. For example, deep learning models trained on MPRA data have been used to optimize 5' untranslated regions (UTRs) for mRNA translation, enabling tailored designs that enhance gene-editing efficiency in the therapeutic context. This could make mRNA-based treatments more effective, as MPRAs also help identify how genetic variants affect gene expression, which is used in precision medicine and developing personalized treatments. Machine learning models trained on MPRA data can predict how different sequences impact gene activity, making it easier to design reporter genes that respond in specific ways. Combining MPRAs with next-gen sequencing also makes reporter gene experiments faster and more scalable. These advances could even improve mRNA-based vaccines and therapeutics by optimizing untranslated regions (UTRs) to boost stability and translation. For instance, modular MPRAs have uncovered context-specific regulatory sequences linked to type 2 diabetes, revealing enhancer-promoter interactions dependent on cell-specific transcription factors like HNF1. Similarly, MPRA screens of cardiac enhancer variants have pinpointed functional noncoding sequences influencing QT interval variability, directly linking genetic variation to disease-associated gene dysregulation.
=== Menopause === The end of ovulation and the beginning of menopause can result in hyperandrogenism. During this transition, the body stops releasing estrogen at a faster rate than it stops releasing androgens. In some cases, the difference between the lower estrogen levels and higher androgen levels can produce hyperandrogenism. A decrease in sex hormone levels while the free androgen index increases can also contribute to this process.
=== EC 1.2.1 With NAD+ or NADP+ as acceptor === EC 1.2.1.1: deleted, replaced by EC 1.1.1.284, S-(hydroxymethyl)glutathione dehydrogenase and EC 4.4.1.22, S-(hydroxymethyl)glutathione synthase EC 1.2.1.2: Now EC 1.17.1.9, formate dehydrogenase EC 1.2.1.3: aldehyde dehydrogenase (NAD+) EC 1.2.1.4: aldehyde dehydrogenase (NADP+) EC 1.2.1.5: aldehyde dehydrogenase (NAD(P)+) EC 1.2.1.6: deleted (was benzaldehyde dehydrogenase) EC 1.2.1.7: benzaldehyde dehydrogenase (NADP+) EC 1.2.1.8: betaine-aldehyde dehydrogenase EC 1.2.1.9: glyceraldehyde-3-phosphate dehydrogenase (NADP+) EC 1.2.1.10: acetaldehyde dehydrogenase (acetylating) EC 1.2.1.11: aspartate-semialdehyde dehydrogenase EC 1.2.1.12: glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) EC 1.2.1.13: glyceraldehyde-3-phosphate dehydrogenase (NADP+) (phosphorylating) EC 1.2.1.14: Now EC 1.1.1.205, IMP dehydrogenase EC 1.2.1.15: malonate-semialdehyde dehydrogenase EC 1.2.1.16: succinate-semialdehyde dehydrogenase [NAD(P)+] EC 1.2.1.17: glyoxylate dehydrogenase (acylating) EC 1.2.1.18: malonate-semialdehyde dehydrogenase (acetylating) EC 1.2.1.19: aminobutyraldehyde dehydrogenase EC 1.2.1.20: glutarate-semialdehyde dehydrogenase EC 1.2.1.21: glycolaldehyde dehydrogenase EC 1.2.1.22: lactaldehyde dehydrogenase EC 1.2.1.23: 2-oxoaldehyde dehydrogenase (NAD+) EC 1.2.1.24: succinate-semialdehyde dehydrogenase (NAD+) EC 1.2.1.25: branched-chain α-keto acid dehydrogenase system EC 1.2.1.26: 2,5-dioxovalerate dehydrogenase EC 1.2.1.27: methylmalonate-semialdehyde dehydrogenase (CoA-acylating) EC 1.2.1.28: benzaldehyde dehydrogenase (NAD+) EC 1.2.1.29: aryl-aldehyde dehydrogenase EC 1.2.1.30: aryl-aldehyde dehydrogenase (NADP+) EC 1.2.1.31: L-aminoadipate-semialdehyde dehydrogenase EC 1.2.1.32: aminomuconate-semialdehyde dehydrogenase EC 1.2.1.33: (R)-dehydropantoate dehydrogenase EC 1.2.1.34: Now EC 1.1.1.131, mannuronate reductase EC 1.2.1.35: Now EC 1.1.1.203, uronate dehydrogenase EC 1.2.1.36: retinal dehydrogenase EC 1.2.1.37: Now EC 1.17.1.4, xanthine dehydrogenase EC 1.2.1.38: N-acetyl-γ-glutamyl-phosphate reductase EC 1.2.1.39: phenylacetaldehyde dehydrogenase EC 1.2.1.40: part of EC 1.14.13.15, cholestanetriol 26-monooxygenase EC 1.2.1.41: glutamate-5-semialdehyde dehydrogenase EC 1.2.1.42: hexadecanal dehydrogenase (acylating) EC 1.2.1.43: Now EC 1.17.1.10, formate dehydrogenase (NADP+) EC 1.2.1.44: cinnamoyl-CoA reductase EC 1.2.1.45: Now EC 1.1.1.312, 2-hydroxy-4-carboxymuconate semialdehyde hemiacetal dehydrogenase EC 1.2.1.46: formaldehyde dehydrogenase EC 1.2.1.47: 4-trimethylammoniobutyraldehyde dehydrogenase EC 1.2.1.48: long-chain-aldehyde dehydrogenase EC 1.2.1.49: 2-oxoaldehyde dehydrogenase (NADP+) EC 1.2.1.50: long-chain-fatty-acyl-CoA reductase EC 1.2.1.51: pyruvate dehydrogenase (NADP+) EC 1.2.1.52: deleted 2025 (was oxoglutarate dehydrogenase (NADP+)) EC 1.2.1.53: 4-hydroxyphenylacetaldehyde dehydrogenase EC 1.2.1.54: γ-guanidinobutyraldehyde dehydrogenase EC 1.2.1.55: Now EC 1.1.1.279, (R)-3-hydroxyacid-ester dehydrogenase EC 1.2.1.56: Now EC 1.1.1.280, (S)-3-hydroxyacid-ester dehydrogenase EC 1.2.1.57: butanal dehydrogenase EC 1.2.1.58: phenylglyoxylate dehydrogenase (acylating) EC 1.2.1.59: glyceraldehyde-3-phosphate dehydrogenase (NAD(P)+) EC 1.2.1.60: 5-carboxymethyl-2-hydroxymuconic-semialdehyde dehydrogenase EC 1.2.1.61: 4-hydroxymuconic-semialdehyde dehydrogenase EC 1.2.1.62: 4-formylbenzenesulfonate dehydrogenase EC 1.2.1.63: 6-oxohexanoate dehydrogenase EC 1.2.1.64: 4-hydroxybenzaldehyde dehydrogenase (NAD+) EC 1.2.1.65: salicylaldehyde dehydrogenase EC 1.2.1.66: Now EC 1.1.1.306, S-(hydroxymethyl)mycothiol dehydrogenase EC 1.2.1.67: vanillin dehydrogenase EC 1.2.1.68: coniferyl-aldehyde dehydrogenase EC 1.2.1.69: fluoroacetaldehyde dehydrogenase EC 1.2.1.70: glutamyl-tRNA reductase EC 1.2.1.71: succinylglutamate-semialdehyde dehydrogenase EC 1.2.1.72: erythrose-4-phosphate dehydrogenase EC 1.2.1.73: sulfoacetaldehyde dehydrogenase EC 1.2.1.74: abieta-7,13-dien-18-al dehydrogenase EC 1.2.1.75: malonyl CoA reductase (malonate semialdehyde-forming) EC 1.2.1.76: succinate-semialdehyde dehydrogenase (acylating) EC 1.2.1.77: 3,4-dehydroadipyl-CoA semialdehyde dehydrogenase (NADP+) EC 1.2.1.78: 2-formylbenzoate dehydrogenase EC 1.2.1.79: succinate-semialdehyde dehydrogenase (NADP+) EC 1.2.1.80: long-chain acyl-[acyl-carrier-protein] reductase EC 1.2.1.81: sulfoacetaldehyde dehydrogenase (acylating) EC 1.2.1.82: β-apo-4′-carotenal oxygenase EC 1.2.1.83: 3-succinoylsemialdehyde-pyridine dehydrogenase EC 1.2.1.84: alcohol-forming fatty acyl-CoA reductase EC 1.2.1.85: 2-hydroxymuconate-6-semialdehyde dehydrogenase EC 1.2.1.86: geranial dehydrogenase EC 1.2.1.87: propanal dehydrogenase (CoA-propanoylating) EC 1.2.1.88: L-glutamate γ-semialdehyde dehydrogenase EC 1.2.1.89: D-glyceraldehyde dehydrogenase (NADP+) EC 1.2.1.90: glyceraldehyde-3-phosphate dehydrogenase [NAD(P)+] EC 1.2.1.91: 3-oxo-5,6-dehydrosuberyl-CoA semialdehyde dehydrogenase EC 1.2.1.92: 3,6-anhydro-α-L-galactose dehydrogenase EC 1.2.1.93: formate dehydrogenase (NAD+, ferredoxin). Now EC 1.17.1.11, formate dehydrogenase (NAD+, ferredoxin) * EC 1.2.1.94: farnesal dehydrogenase EC 1.2.1.95: L-2-aminoadipate reductase EC 1.2.1.96: 4-hydroxybenzaldehyde dehydrogenase (++) EC 1.2.1.97: 3-sulfolactaldehyde dehydrogenase EC 1.2.1.98: 2-hydroxy-2-methylpropanal dehydrogenase EC 1.2.1.99: 4-(γ-glutamylamino)butanal dehydrogenase EC 1.2.1.100: 5-formyl-3-hydroxy-2-methylpyridine 4-carboxylic acid 5-dehydrogenase EC 1.2.1.101: L-tyrosine reductase EC 1.2.1.102: isopyridoxal dehydrogenase (5-pyridoxate-forming) EC 1.2.1.103: [amino-group carrier protein]-6-phospho-L-2-aminoadipate reductase EC 1.2.1.104: pyruvate dehydrogenase system EC 1.2.1.105: 2-oxoglutarate dehydrogenase system EC 1.2.1.106: [amino-group carrier protein]-5-phospho-L-glutamate reductase EC 1.2.1.107: glyceraldehyde-3-phosphate dehydrogenase (arsenate-transferring)
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.